Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases

J. Hyánek, Reuben Matalon, P. Rady, S. Szucs, P. Šebesta, J. Matoušková, H. Pejznochová, L. Dubská, H. Přindisová, J. Dvořáková, M. Loučka, V. Martiníková, M. Slancová

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In a representative set of 27 Czech patients suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20μmol/l), polymorphisms of MTHFR 677 C > T, MTHFR 1289 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5884) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1289 and MTRR-Met) was not significantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70% of patients with mHHC were folate reversible, 9 % cobalamin-reversible and 6% pyridoxal phosphate-reversible. 15% of patients-resistant to any supplementation of vitamins are now treated with hetaine or riboflavin.

Original languageEnglish (US)
Pages (from-to)72-76
Number of pages5
JournalKlinicka Biochemie a Metabolismus
Volume10
Issue number2
StatePublished - 2002
Externally publishedYes

Fingerprint

Hyperhomocysteinemia
Polymorphism
Vitamins
Cardiovascular Diseases
Vitamin B 12
Folic Acid
Pyridoxine
Pyridoxal Phosphate
Riboflavin
Incidence

Keywords

  • Cobalamin
  • Folate
  • Mild hyperhomocysteinaemia vitamin supplementation
  • Polymorphism of MTHFR and MTRR
  • Pyridoxal phosphate

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Endocrinology
  • Applied Microbiology and Biotechnology

Cite this

Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases. / Hyánek, J.; Matalon, Reuben; Rady, P.; Szucs, S.; Šebesta, P.; Matoušková, J.; Pejznochová, H.; Dubská, L.; Přindisová, H.; Dvořáková, J.; Loučka, M.; Martiníková, V.; Slancová, M.

In: Klinicka Biochemie a Metabolismus, Vol. 10, No. 2, 2002, p. 72-76.

Research output: Contribution to journalArticle

Hyánek, J, Matalon, R, Rady, P, Szucs, S, Šebesta, P, Matoušková, J, Pejznochová, H, Dubská, L, Přindisová, H, Dvořáková, J, Loučka, M, Martiníková, V & Slancová, M 2002, 'Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases', Klinicka Biochemie a Metabolismus, vol. 10, no. 2, pp. 72-76.
Hyánek, J. ; Matalon, Reuben ; Rady, P. ; Szucs, S. ; Šebesta, P. ; Matoušková, J. ; Pejznochová, H. ; Dubská, L. ; Přindisová, H. ; Dvořáková, J. ; Loučka, M. ; Martiníková, V. ; Slancová, M. / Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases. In: Klinicka Biochemie a Metabolismus. 2002 ; Vol. 10, No. 2. pp. 72-76.
@article{4a369711e6454d1d9796f5b22a15feba,
title = "Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases",
abstract = "In a representative set of 27 Czech patients suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20μmol/l), polymorphisms of MTHFR 677 C > T, MTHFR 1289 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5884) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1289 and MTRR-Met) was not significantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70{\%} of patients with mHHC were folate reversible, 9 {\%} cobalamin-reversible and 6{\%} pyridoxal phosphate-reversible. 15{\%} of patients-resistant to any supplementation of vitamins are now treated with hetaine or riboflavin.",
keywords = "Cobalamin, Folate, Mild hyperhomocysteinaemia vitamin supplementation, Polymorphism of MTHFR and MTRR, Pyridoxal phosphate",
author = "J. Hy{\'a}nek and Reuben Matalon and P. Rady and S. Szucs and P. Šebesta and J. Matouškov{\'a} and H. Pejznochov{\'a} and L. Dubsk{\'a} and H. Přindisov{\'a} and J. Dvoř{\'a}kov{\'a} and M. Loučka and V. Martin{\'i}kov{\'a} and M. Slancov{\'a}",
year = "2002",
language = "English (US)",
volume = "10",
pages = "72--76",
journal = "Biochemia Clinica Bohemoslovaca",
issn = "1210-7921",
publisher = "Czech Medical Association J.E. Purkyne",
number = "2",

}

TY - JOUR

T1 - Hyperhomocysteinaemia, MTHFR or MTRR polymorphism and vitamin supplementation in Czech patients suffering from cardiovascular diseases

AU - Hyánek, J.

AU - Matalon, Reuben

AU - Rady, P.

AU - Szucs, S.

AU - Šebesta, P.

AU - Matoušková, J.

AU - Pejznochová, H.

AU - Dubská, L.

AU - Přindisová, H.

AU - Dvořáková, J.

AU - Loučka, M.

AU - Martiníková, V.

AU - Slancová, M.

PY - 2002

Y1 - 2002

N2 - In a representative set of 27 Czech patients suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20μmol/l), polymorphisms of MTHFR 677 C > T, MTHFR 1289 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5884) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1289 and MTRR-Met) was not significantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70% of patients with mHHC were folate reversible, 9 % cobalamin-reversible and 6% pyridoxal phosphate-reversible. 15% of patients-resistant to any supplementation of vitamins are now treated with hetaine or riboflavin.

AB - In a representative set of 27 Czech patients suffering from cardiovascular disease with mild hyperhomocysteinaemia (mHHC) (> 20μmol/l), polymorphisms of MTHFR 677 C > T, MTHFR 1289 and MTRR-Met were followed. The above mentioned patients were selected from a large group of patients (n=5884) according to intensity of their clinical and metabolic status. A significantly high incidence of MTHFR 677 C > T polymorphism was observed (p < 0,001). The incidence of other types of polymorphism (MTHFR 1289 and MTRR-Met) was not significantly changed. All hyperhomocysteinaemic patients were supplemented with critical vitamins (i.e. folate, cobalamin and pyridoxine). In 70% of patients with mHHC were folate reversible, 9 % cobalamin-reversible and 6% pyridoxal phosphate-reversible. 15% of patients-resistant to any supplementation of vitamins are now treated with hetaine or riboflavin.

KW - Cobalamin

KW - Folate

KW - Mild hyperhomocysteinaemia vitamin supplementation

KW - Polymorphism of MTHFR and MTRR

KW - Pyridoxal phosphate

UR - http://www.scopus.com/inward/record.url?scp=18344367818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344367818&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 72

EP - 76

JO - Biochemia Clinica Bohemoslovaca

JF - Biochemia Clinica Bohemoslovaca

SN - 1210-7921

IS - 2

ER -